NCT04584307撤回2 期
Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (Immuno-POWER Trial): Big Ten Cancer Research Consortium BTCRC-MM19-428
Natalie Callendar0 个研究点开始时间: 2021年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 主要终点
- Progression-Free Survival
研究概览
简要总结
The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID) in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy following second unplanned autologous peripheral blood stem cell transplant (PBSCT) for relapsed multiple myeloma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of relapsed or relapsed/refractory multiple myeloma who will be undergoing a second unplanned autologous peripheral blood stem cell transplant for their disease.
- •Age ≥ 18 years at the time of consent.
- •Written informed consent and HIPAA authorization for release of personal health information.
- •NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
- •ECOG Performance Status of 0, 1, or 2 within 14 days prior to registration.
- •Patients must have had measurable disease, defined as one of the following:
- •monoclonal protein (M-protein): ≥ 0.5g/dL on serum protein electrophoresis or ≥ 200 mg of monoclonal protein on a 24-hour urine protein or involved serum light chain ≥ 10 mg/dl at time of relapse, leading to decision to proceed to transplant; or
- •biopsy proven plasmacytoma that can be assessed by physical exam or imaging; or
- •if non-secretory, ≥10% plasma cells on BM biopsy/aspirate at time of relapse or plasmacytoma as described above.
- •NOTE: Urine protein electrophoresis (UPEP) (on a 24-h collection) is required, no substitute method is acceptable. Urine must be assessed to establish response if the baseline urine M-spike is ≥ 200 mg/24 h at the time of enrollment. Please note that if both serum and urine M-components are present prior to transplant, both should be assessed in order to evaluate response.
- •Patients may have received any number and type of previous treatments for myeloma including elotuzumab or pomalidomide, but not simultaneous administration of these two agents.
- •Previous allogeneic transplant is allowed provided the patient is not receiving ongoing therapy for GVHD.
- •Previous CAR-T transplantation or other BMCA directed therapy is also allowed provided there is no evidence of residual cytokine release syndrome or cytokine release encephalopathy syndrome.
- •As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.
- •Pomalidomide will not be provided the study and therefore study subjects must have confirmed access to pomalidomide for use during the study established at time of enrollment.
- •Furthermore, subjects must meet all of the following applicable inclusion criteria 45-90 days post-transplant to be treated on this study:
- •Patients must have recovered from transplantation to ≤grade 2 non- hematologic toxicity, with the exception of alopecia.
- •No evidence of progression of myeloma noted within 45 days post-transplant.
- •Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to initiation of treatment.
- •Females of childbearing potential must have two negative pregnancy tests (serum or urine): within 14 days and 24 hours prior to treatment.
- •- NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
- •Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 5 months for females, and 7 months for males after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. Interventions such as IUD, tubal ligation, hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partner's vasectomy, all count as one method. For WOCBP, a second form must also be used.
- •As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.
- •Subjects must be willing to provide BM, stool and blood samples during the study period.
排除标准
- •Active infection requiring systemic therapy.
- •Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least three years. Patients who have undergone a curative procedure for another malignancy are eligible.
- •Active central nervous system (CNS) metastases.
- •Treatment with any investigational drug within 30 days prior to registration.
- •Planned transplant is considered part of tandem approach for newly diagnosed MM
- •History of severe hypersensitivity reaction to any monoclonal antibody.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant women are excluded from this study because pomalidomide is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pomalidomide, breastfeeding should be discontinued if the mother is treated with pomalidomide.
- •Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) might be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment and absolute lymphocyte count >= 350/ul. Such subjects may stay on antiviral therapy during study treatment.
- •Patients with a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection might be enrolled if the viral load by PCR is undetectable with/without active treatment. Such patients may stay on viral therapy while on treatment.
研究组 & 干预措施
Elotuzumab + Pomalidomide
Experimental
Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
干预措施: Elotuzumab (Drug)
Elotuzumab + Pomalidomide
Experimental
Elotuzumab, 10 mg/kg IV, Days 1,8,15,22 for cycles 1 and 2 Elotuzumab, 20 mg/kg IV, Day 1 for cycles 3 + Pomalidomide 2mg PO, Day 1-21 for all cycles
干预措施: Pomalidomide (Drug)
结局指标
主要结局
Progression-Free Survival
时间窗: From enrollment until the time of disease progression, up to 36 months
To estimate progression-free survival (PFS) rate in patients receiving the combination of elotuzumab and pomalidomide who have undergone a second unplanned autologous PBSCT for relapsed multiple myeloma (MM).
次要结局
- Overall Survival(From enrollment until the time of death, up to 36 months)
- Summary of >= Grade 3 Hematologic and Non-Hematologic Toxicities(From enrollment until treatment discontinuation, up to 18 months)
研究者
Natalie Callendar
Sponsor-Investigator
Big Ten Cancer Research Consortium
相似试验
撤回
2 期
Evaluation of the Immune Restoration Potential Of LenalidomideChronic Lymphocytic Leukemia (CLL)NCT02371577University of California, San Diego
已完成
2 期
Pomalidomide for Chronic Graft-versus-Host DiseaseGraft vs Host DiseaseGraft-Versus-Host DiseaseNCT01688466National Cancer Institute (NCI)34
终止
2 期
Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsMultiple MyelomaNCT02188368Oncotherapeutics45
尚未招募
Unknown
EFFECT Trial: Evaluating Fermentable Fibre as a Long COVID TherapyACTRN12624000356561Monash University40
已完成
2 期
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus InfectionHuman Immunodeficiency Virus 1 PositiveSkin Kaposi SarcomaNCT03601806AIDS Malignancy Consortium26